The history of Sildenafil presents a complex case for observers in the drug sector. While initially a phenomenal success, creating huge profits, the exclusivity lapse and the subsequent flood of cheaper alternatives have drastically impacted earnings. This poses questions about the ongoing profitability of analogous drug innovations and suggests th